Sanofi (NASDAQ:SNY) Now Covered by Wolfe Research

Investment analysts at Wolfe Research started coverage on shares of Sanofi (NASDAQ:SNY) in a research report issued to clients and investors on Friday, Briefing.com reports. The firm set a “peer perform” rating on the stock.

A number of other brokerages also recently issued reports on SNY. Royal Bank Of Canada began coverage on Sanofi in a research report on Tuesday, September 8th. They issued a “sector perform” rating for the company. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Weiss Ratings cut shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Wall Street Zen downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Morgan Stanley set a $49.00 price target on Sanofi in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Up 0.1%

NASDAQ SNY opened at $40.23 on Friday. The company has a market capitalization of $97.53 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.21 and a beta of 0.33. The stock has a 50 day moving average price of $43.05 and a 200-day moving average price of $44.02. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. Sanofi has a one year low of $39.18 and a one year high of $52.68.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The company’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter last year, the company earned $3.24 earnings per share. As a group, equities analysts predict that Sanofi will post 5.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently bought and sold shares of SNY. Physician Wealth Advisors Inc. lifted its holdings in Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after buying an additional 379 shares during the period. Western Wealth Management LLC purchased a new stake in shares of Sanofi during the 1st quarter worth $29,000. Leonteq Securities AG lifted its stake in shares of Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after purchasing an additional 297 shares during the last quarter. Fairway Wealth LLC bought a new stake in Sanofi during the first quarter valued at about $32,000. Finally, Purpose Unlimited Inc. purchased a new position in Sanofi in the fourth quarter valued at about $36,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.